Managing cardiotoxicity associated with immune checkpoint inhibitors
Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are availabl...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2019-03-01
|
Series: | Chronic Diseases and Translational Medicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X18301117 |
id |
doaj-b91444971101405b80c7c7722ba90885 |
---|---|
record_format |
Article |
spelling |
doaj-b91444971101405b80c7c7722ba908852021-04-02T13:16:36ZengKeAi Communications Co., Ltd.Chronic Diseases and Translational Medicine2095-882X2019-03-0151614Managing cardiotoxicity associated with immune checkpoint inhibitorsSireesha Upadhrasta0Hadi Elias1Keval Patel2Lei Zheng3Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USADepartment of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USADepartment of Internal Medicine, University of Maryland, Baltimore, MD 21201, USADepartments of Oncology and Surgery, The Pancreatic Cancer Precision Medicine Center of Excellence Program, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD 21287, USA; Corresponding author. 1650 Orleans Street, CRB1, Room 351, Baltimore, MD 21287, USA. Fax: +1 410 614 8217.Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. Keywords: Immune checkpoint inhibitor, Cardiotoxicity, Ipilimumab, Nivolumab, Pembrolizumabhttp://www.sciencedirect.com/science/article/pii/S2095882X18301117 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sireesha Upadhrasta Hadi Elias Keval Patel Lei Zheng |
spellingShingle |
Sireesha Upadhrasta Hadi Elias Keval Patel Lei Zheng Managing cardiotoxicity associated with immune checkpoint inhibitors Chronic Diseases and Translational Medicine |
author_facet |
Sireesha Upadhrasta Hadi Elias Keval Patel Lei Zheng |
author_sort |
Sireesha Upadhrasta |
title |
Managing cardiotoxicity associated with immune checkpoint inhibitors |
title_short |
Managing cardiotoxicity associated with immune checkpoint inhibitors |
title_full |
Managing cardiotoxicity associated with immune checkpoint inhibitors |
title_fullStr |
Managing cardiotoxicity associated with immune checkpoint inhibitors |
title_full_unstemmed |
Managing cardiotoxicity associated with immune checkpoint inhibitors |
title_sort |
managing cardiotoxicity associated with immune checkpoint inhibitors |
publisher |
KeAi Communications Co., Ltd. |
series |
Chronic Diseases and Translational Medicine |
issn |
2095-882X |
publishDate |
2019-03-01 |
description |
Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. Keywords: Immune checkpoint inhibitor, Cardiotoxicity, Ipilimumab, Nivolumab, Pembrolizumab |
url |
http://www.sciencedirect.com/science/article/pii/S2095882X18301117 |
work_keys_str_mv |
AT sireeshaupadhrasta managingcardiotoxicityassociatedwithimmunecheckpointinhibitors AT hadielias managingcardiotoxicityassociatedwithimmunecheckpointinhibitors AT kevalpatel managingcardiotoxicityassociatedwithimmunecheckpointinhibitors AT leizheng managingcardiotoxicityassociatedwithimmunecheckpointinhibitors |
_version_ |
1721565615597027328 |